<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023565</url>
  </required_header>
  <id_info>
    <org_study_id>MOXOD001</org_study_id>
    <nct_id>NCT04023565</nct_id>
  </id_info>
  <brief_title>Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome</brief_title>
  <acronym>COMPOSER</acronym>
  <official_title>Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sergey V. Nedogoda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Volgograd State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is to assess the angioprotective effects of antihypertensive combination&#xD;
      therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial&#xD;
      hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) &gt; 10 m/s on&#xD;
      the previously administered two-component combination antihypertensive therapy.&#xD;
&#xD;
      Open-label non-comparative prospective study for 24 week for each patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to European Society of Cardiology (ESC) and the European Society of Hypertension&#xD;
      (ESH) Guidelines for the management of arterial hypertension 2018 in case of previous&#xD;
      combination at full dose does not allow to achieve the target Blood Pressure (BP), that&#xD;
      therapy might be switch to different two-drug combination.&#xD;
&#xD;
      The study will enroll 120 hypertensive (Grade 1, 2 Arterial Hypertension (AH): Systolic Blood&#xD;
      Pressure (SBP) 140-179 mm Hg and Diastolic Blood Pressure (DBP) 90-109 mm Hg According to&#xD;
      ESC/ESH Guidelines 2018) patients with metabolic syndrome who met the inclusion criteria when&#xD;
      treated with Angiotensin Converting Enzyme Inhibition(ACEi) /Angiotensin Receptor Blocker&#xD;
      (ARB) + hydrochlorothiazide (HCTZ)/indapamide or +amlodipine (30 patients in each group):&#xD;
&#xD;
        1. ACEi (except perindopril) + diuretic (HCTZ or indapamide)&#xD;
&#xD;
        2. ACEi (except perindopril) + amlodipine&#xD;
&#xD;
        3. ARB+ diuretic (HCTZ or indapamide)&#xD;
&#xD;
        4. ARB+ amlodipine&#xD;
&#xD;
      Upon obtaining Inform Consent the previous therapy will be discontinued according to&#xD;
      recommendations (gradually or at once).&#xD;
&#xD;
      After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be&#xD;
      prescribed.&#xD;
&#xD;
      If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg&#xD;
      + moxonidine 0.6 mg a day (given as two divided doses).&#xD;
&#xD;
      FORBIDDEN TREATMENTS:&#xD;
&#xD;
      Any other antihypertensives (calcium antagonists, Î²-blockers, ACEi except perindopril, ARBs,&#xD;
      diuretics) for routine AH management (except those used to resolve the uncontrolled&#xD;
      hypertension).&#xD;
&#xD;
      CRITERIA FOR PREMATURE PATIENT WITHDRAWAL FROM THE STUDY:&#xD;
&#xD;
        1. Withdrawal of informed consent by the patient at any time of the study.&#xD;
&#xD;
        2. Need for uncontrolled hypertension management occurring more than 2 times weekly&#xD;
           throughout the 2 consecutive weeks during study period.&#xD;
&#xD;
        3. Need for the third antihypertensive drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulse wave velocity (PWV)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the PWV after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Central Blood Pressure (BP)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the central BP changes (systolic BP, aortic pulse BP) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Reflected wave index</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the reflected wave index after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in carbohydrate and lipid metabolism parameters markers</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the homeostatic model assessment - insulin resistance (HOMA-IR), and lipid metabolism (total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL)) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the adipokine level</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the adipokine level (leptin) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Inflammatory marker level</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the high sensible C-reactive Protein (hs-CRP) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the renin-angiotensin-aldosterone system hyperactivation marker level</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the renin-angiotensin-aldosterone system hyperactivation marker level (plasma aldosterone-to-renin ratio) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the sympathoadrenal system hyperactivation marker levels</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>To assess the sympathoadrenal system hyperactivation marker levels (urine excretion adrenaline, noradrenaline, dofamine levels) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieved target BP level</measure>
    <time_frame>Week 4, Week 12, Week 24</time_frame>
    <description>To assess the proportion of patients (%) achieving target BP levels &lt;130/80 mm Hg at Week 4, Week 12, Week 24</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Arterial Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>perindopril + moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perindopril + moxonidine</intervention_name>
    <description>After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.&#xD;
If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).&#xD;
If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).</description>
    <arm_group_label>perindopril + moxonidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients (male and female) aging 18 to 70 years.&#xD;
&#xD;
          2. Grade 1, 2 AH (SBP 140-179 mm Hg and/or DBP 90-109 mm Hg according 2018 ESH/ESC&#xD;
             guidelines)&#xD;
&#xD;
          3. PWV &gt; 10 m/s&#xD;
&#xD;
          4. Previous two-component antihypertensive therapy (ACEi/ARB+ diuretic (HCTZ or&#xD;
             indapamide) or ACEI/ARB + amlodipine) during at least 6 months prior to the study&#xD;
             enrollment&#xD;
&#xD;
          5. Metabolic syndrome diagnosed by the 2009 Russian Society of Cardiology (RSC) National&#xD;
             Guidelines criteria&#xD;
&#xD;
               1. THE MAIN SIGN: central (abdominal) obesity defined as waist circumference (WC)&#xD;
                  above 80 cm in women and above 94 cm in men.&#xD;
&#xD;
               2. ADDITIONAL CRITERIA:&#xD;
&#xD;
             i. - arterial hypertension (BP â¥ 130/85 mm Hg) ii. - high triglycerides (â¥ 1.7 mmol/l)&#xD;
             iii. - decreased HDL-cholesterol (&lt;1.0 mmol/l for men; &lt;1.2 mmol/l for women) iv. -&#xD;
             increased LDL-cholesterol &gt; 3.0 mmol/l v. - fasting hyperglycaemia (fasting plasma&#xD;
             glucose â¥ 6.1 mmol/l) vi. - impaired glucose tolerance (plasma glucose at 2 hours&#xD;
             after glucose load from â¥7.8 to â¤11.1 mmol/l)&#xD;
&#xD;
             Metabolic syndrome is defined as presence of central obesity and two of the additional&#xD;
             criteria.&#xD;
&#xD;
          6. Body Mass Index (BMI) &gt;30 kg/m2.&#xD;
&#xD;
          7. For female patients with childbearing potential: negative pregnancy test and&#xD;
             willingness to use reliable methods of contraception until the study treatment&#xD;
             completion&#xD;
&#xD;
          8. Voluntarily signed informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications for using ACEi and imidazoline receptor agonists.&#xD;
&#xD;
          2. Administration of perindopril or moxonidine during 6 months before the study onset.&#xD;
&#xD;
          3. Metformin therapy for prophylaxis diabetes mellitus type 2 in patients with&#xD;
             pre-diabetes, which had been started within 6 months before the study enrollment. (If&#xD;
             a patient receives metformin for a long time, i.e., more than 6 months, he/she can be&#xD;
             included in the study, and metformin discontinuation is not required).&#xD;
&#xD;
          4. Statin and/or fibrate therapy started within 6 months before the study enrollment. (If&#xD;
             a patient receives statins and/or fibrates for a long time, i.e., more than 6 months,&#xD;
             he/she can be included in the study, and discontinuation of statins and fibrates is&#xD;
             not required).&#xD;
&#xD;
          5. Current diagnosis of unstable angina, acute and subacute myocardial infarction.&#xD;
&#xD;
          6. Heart failure of any functional class.&#xD;
&#xD;
          7. Grade 3 AH (â¥ 180/110 mm Hg).&#xD;
&#xD;
          8. Sinus bradycardia (heart rate â¤50/min).&#xD;
&#xD;
          9. Type 1 or 2 diabetes mellitus.&#xD;
&#xD;
         10. Severe comorbidities, including mental diseases.&#xD;
&#xD;
         11. Acute conditions (infections, exacerbation of chronic diseases, injuries, surgical&#xD;
             interventions).&#xD;
&#xD;
         12. Alcohol abuse.&#xD;
&#xD;
         13. Pregnancy and lactation.&#xD;
&#xD;
         14. Serious renal dysfunction (Estimated Glomerular Filtration Rate (eGFR) by Chronic&#xD;
             Kidney Disease Epidemiology Collaboration (CKD-EPI) â¤30 ml/min/1.73 m2).&#xD;
&#xD;
         15. Serious hepatic dysfunction&#xD;
&#xD;
         16. Malignancies diagnosed and treated during the previous 5 years prior to study&#xD;
             enrollment.&#xD;
&#xD;
         17. Inability to understand the study and to give informed consent for participation in&#xD;
             it.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey V. Nedogoda, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Volgograd State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergey V. Nedogoda, Professor</last_name>
    <phone>+79023643226</phone>
    <email>nedogodasv@rambler.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Therapy and Endocrinology</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey V. Nedogoda, Professor</last_name>
      <phone>+79023643226</phone>
      <email>nedogodasv@rambler.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Volgograd State Medical University</investigator_affiliation>
    <investigator_full_name>Sergey V. Nedogoda</investigator_full_name>
    <investigator_title>Dr.Med.Sc., Professor</investigator_title>
  </responsible_party>
  <keyword>perindopril</keyword>
  <keyword>moxonidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

